ASCO 2022 Conference Coverage
ASCO 2022 on Safety & Clinical Activity of MEDI5752, a PD-1/CTLA-4 Bispecific Checkpoint Inhibitor, as Monotherapy With Advanced RCC: Preliminary Results From the FTIH Trial
By
ASCO 2022 Conference Coverage
FEATURING
Laurence Albiges
By
ASCO 2022 Conference Coverage
FEATURING
Laurence Albiges
Comments 0
Login to view comments.
Click here to Login
